Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

NCT03419897 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

249

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Tislelizumab

Sponsor

BeiGene